Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings

Emily Wasserman Big Pharma can celebrate a bright point. Arizona's top court ruled that drugmakers don't have an obligation to warn patients directly about safety risks of their ...

J&J loses bid to dismiss false advertising lawsuit over baby products

Carly Helfand Johnson & Johnson was hoping to put a marketing case around its Bedtime Products for babies to rest, but a federal judge isn't having it. FiercePharma News

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

ProPublica: Safety questions over GSK’s Advair linger after years on the asthma throne

Carly Helfand U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $ 8 billion ...

FDA staffers raise doubts over key Vertex combo

Carly Helfand As an FDA review nears for Vertex's Kalydeco-lumacaftor tandem–approval of which could help Kalydeco reach 10 times the number of cystic fibrosis patients it ...

BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Eric Palmer Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But Erbitux no longer fits in the sweet spot ...

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Damian Garde Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase ...

J&J awaits jury verdict over Risperdal patient’s breast development

Tracy Staton Did Johnson & Johnson hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia ...

Court’s decision on Namenda ‘hard switch’ could spill over into precedent

Tracy Staton Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release ...

Billionaire Singer threatens to sue AbbVie over Shire breakup

Carly Helfand A $ 1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $ 55 billion agreement. But investors? At least one ...

Amgen-Sandoz squabble over Neupogen copy could reshape biosim marketing

Tracy Staton The patent provisions of the Hatch-Waxman Act are familiar to both sides of the branded-generic fence by now. Not so when it comes to similar procedures related ...

Top execs bicker over Sanofi’s plan to unload $8B portfolio of old drugs

Arlene Weintraub Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. ...
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS